Abnormalities of retinoblastoma gene expression in hematological malignancies.

Abstract:

:The human retinoblastoma gene product which is involved in cell cycle control and also acts as a transcriptional repressor of genes involved in growth control, is constitutively expressed as a phosphoprotein in normal hemopoietic cells. Abnormalities of the retinoblastoma gene expression leading to loss of protein expression either due to structural changes, mutations or transcriptional abnormalities have been found in a variety of hematological malignancies. There is evidence that loss of Rb protein expression is particularly associated with tumour progression and an adverse response to therapy which may be linked to the biological effect of Rb protein loss on the growth characteristics of tumour cells.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Zhu YM,Haynes AP,Keith FJ,Russell NH

doi

10.3109/10428199509064923

subject

Has Abstract

pub_date

1995-06-01 00:00:00

pages

61-7

issue

1-2

eissn

1042-8194

issn

1029-2403

journal_volume

18

pub_type

杂志文章,评审
  • Prevention and treatment of hepatic venocclusive disease after high-dose cytoreductive therapy.

    abstract::Venocclusive disease of the liver (VOD) is one of the most common and serious complications following stem cell transplantation. High-dose chemotherapy or chemoradiotherapy injures the structures of Zone 3 of the liver acinus and produces the clinical syndrome of hepatomegaly or right upper quadrant pain, jaundice, an...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199809059219

    authors: Richardson P,Bearman SI

    更新日期:1998-10-01 00:00:00

  • Concurrent chronic lymphocytic leukemia/small lymphocytic lymphoma and hairy cell leukemia: clinical, pathologic and molecular features.

    abstract::Simultaneous occurrence of hairy cell leukemia (HCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (termed CLL) is very rare. Clinical characteristics, pathology and management of these cases have not been well described. We present six patients with CLL and HCL or HCL variant (HCL-v). Of six patients, t...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1797007

    authors: Obiorah IE,Francischetti IMB,Wang HW,Ahn IE,Wang W,Raffeld M,Kreitman RJ,Wiestner A,Calvo KR

    更新日期:2020-12-01 00:00:00

  • P-Glycoprotein Expression in Drug-Resistant Chronic Lymphoproliferative Disorder.

    abstract::Peripheral blood lymphocytes from 60 patients with drug-resistant chronic lymphoproliferative disorders (LPD) were examined for expression of P-glycoprotein (P-gp) by direct immunofluorescence (IF) test using monoclonal antibody (MoAb) C219. Four of the 15 patients with prolymphocytic leukaemia (PLL), and both patient...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199109067633

    authors: Majumdar G,Singh AK

    更新日期:1991-01-01 00:00:00

  • Alterations of P53 and RB genes and the evolution of the accelerated phase of chronic myeloid leukemia.

    abstract::Using the single-strand conformation polymorphism and heteroduplex analyses, the P53 and RB genes were analyzed in cell samples from twenty-eight patients with chronic myeloid leukemia (CML) both at diagnosis and at the onset of accelerated phase (AP) of the disease. No alterations of the P53 or RB genes were found in...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190009059278

    authors: Beck Z,Kiss A,Tóth FD,Szabó J,Bácsi A,Balogh E,Borbély A,Telek B,Kovács E,Oláh E,Rak K

    更新日期:2000-08-01 00:00:00

  • Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.

    abstract::Recent clinical data suggest remarkable activity of ibrutinib, the first-in-class covalent inhibitor of Bruton's tyrosine kinase (BTK), in chronic lymphocytic leukemia (CLL), as well as excellent activity in other B cell malignancies, including in particular mantle cell lymphoma and Waldenstrom macroglobulinemia. This...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2013.803226

    authors: Brown JR

    更新日期:2014-02-01 00:00:00

  • In vivo pharmacodynamic effects of Hu1D10 (remitogen), a humanized antibody reactive against a polymorphic determinant of HLA-DR expressed on B cells.

    abstract::The humanized monoclonal antibody Hu1D10 (Remitogen, Protein Design Labs, Fremont, CA) recognizes a polymorphic determinant of human leukocyte antigen-DR expressed on the majority of B-cell lymphomas and on normal B cells of most individuals. Hu1D10 mediates complement-mediated cytotoxicity, antibody-dependent cell-me...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190290026376

    authors: Shi JD,Bullock C,Hall WC,Wescott V,Wang H,Levitt DJ,Klingbeil CK

    更新日期:2002-06-01 00:00:00

  • Treatment of Philadelphia Chromosome Positive (Ph +) Chronic Myelogenous Leukemia in Blast Crisis and Ph + Acute Leukemia with High Dose Cytosine Arabinoside (HDARAC).

    abstract::High dose cytosine arabinoside (HDARAC) was administered to eleven patients in the blastic phase of Philadelphia (Ph) chromosome positive chronic myelogenous leukemia (CML). Four patients presented in blastic phase and in seven patients blastic transformation had evolved from a previous chronic phase. All patients had...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199109068053

    authors: Kempin S,Arlin Z,Berman E,Gee T,Mertelsmann R,Andreeff M,Kolitz J,Jhanwar S,Myers J,Clarkson B

    更新日期:1991-01-01 00:00:00

  • The International Prognostic Index predicts outcome after histological transformation of low-grade non-Hodgkin lymphoma.

    abstract::Histological transformation of low-grade non-Hodgkin lymphoma (NHL) to diffuse large cell NHL is well recognized and is associated with a poor prognosis. We sought to determine the overall outcome and the factors that affect survival in patients with histological transformation of low-grade NHL. Between November 1979 ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190600757894

    authors: Micallef IN,Remstein ED,Ansell SM,Colgan JP,Inwards DJ,Johnston PB,Lewis JT,Markovic SN,Porrata LF,White WL,Witzig TE,Ristow K,Habermann TM

    更新日期:2006-09-01 00:00:00

  • Familial erythroleukemia: a distinct clinical and genetic type of familial leukemias.

    abstract::A family with erythroleukemia is presented, in which father and son were diagnosed at the same age, but 20 years apart, with almost identical clinical and morphological features of the disease. No environmental factors were identified. The karyotypic abnormalities of the bone marrow blasts in the son demonstrated 2 ma...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199809057551

    authors: Novik Y,Marino P,Makower DF,Wiernik PH

    更新日期:1998-07-01 00:00:00

  • Expression of Akt (protein kinase B) and its isoforms in malignant lymphomas.

    abstract::Akt (protein kinase B) is a serine/threonine kinase involved in the regulation of cell survival signals. Akt is expressed in T- and B-lymphocytes and is activated in response to cytokine and antigen-receptor stimulation. Three isoforms of Akt have been identified, Akt-1, -2 and -3, but the expression pattern and speci...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500159944

    authors: Fillmore GC,Wang Q,Carey MJ,Kim CH,Elenitoba-Johnson KS,Lim MS

    更新日期:2005-12-01 00:00:00

  • Clinical significance of detecting p53 protein in Burkitt lymphoma and B-cell acute lymphoblastic leukemia using immunocytochemistry.

    abstract::P53 protein expression in malignant cells of five patients with Burkitt lymphoma (BL) and from two patients with B-cell acute lymphoblastic leukemia (B-ALL) was examined with anti p53 protein monoclonal antibodies PAb1801, PAb240 and p53-D07 using an immunocytochemical technique. Four of the seven patients were positi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199809058368

    authors: Nagai J,Kigasawa H,Koga N,Katoh A,Nishihira H,Nagao T

    更新日期:1998-02-01 00:00:00

  • Bone marrow transplantation in hemophagocytic lymphohistiocytosis.

    abstract::Two important syndromes of hemophagocytic lymphohistiocytosis (HLH) have to be considered in infants and young children with recurrent fever, organomegaly and cytopenias. Familial hemophagocytic lymphohistiocytosis (FHLH) is a genetically heterogeneous autosomal recessive disease with histiocytic and lymphocytic infil...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190109057957

    authors: Dürken M,Finckenstein FG,Janka GE

    更新日期:2001-03-01 00:00:00

  • Abnormal expression of CD66a promotes proliferation and inhibits apoptosis of human leukemic B cells in vitro.

    abstract::The aberrant expression of myeloid antigen CD66 on acute B-lymphoblastic leukemia (B-ALL) cells is a well-documented phenomenon. CD66a is a major subtype of the CD66 family which plays a dual role in different cancers, and the contradictory effect may depend on the isoform ratio of CD66a-4L to CD66a-4S. Although the a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2014.913287

    authors: Zhao W,Zhang Y,Liu D,Zhong L,He Q,Zhao Y

    更新日期:2015-01-01 00:00:00

  • IKZF1 rs4132601 polymorphism and acute lymphoblastic leukemia susceptibility: a meta-analysis.

    abstract::Several studies have been conducted to examine the association between IKZF1 rs4132601 polymorphism and acute lymphoblastic leukemia (ALL) risk. However, the conclusions remain controversial. We therefore performed a meta-analysis. PubMed, Embase, Web of Science, Weipu and Chinese Biomedical Literature (CBM) databases...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,meta分析

    doi:10.3109/10428194.2014.939965

    authors: Li S,Ren L,Fan L,Wang G

    更新日期:2015-04-01 00:00:00

  • Possible immortalization of Hodgkin and Reed-Sternberg cells: telomerase expression, lengthening of telomere, and inhibition of apoptosis by NF-kappaB expression.

    abstract::Telomerase, an enzyme associated with cellular immortality, is expressed on malignant tumor cells. Deregulation of telomerase is thought to facilitate tumorigenesis and cellular immortality by providing cancer cells with unlimited proliferation capacity. Hodgkin and Reed-Sternberg (H&RS) cells are generally considered...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190109057992

    authors: Ohshima K,Sugihara M,Haraoka S,Suzumiya J,Kanda M,Kawasaki C,Shimazaki K,Kikuchi M

    更新日期:2001-04-01 00:00:00

  • Treatment of multiple myeloma in the elderly: realities and hopes.

    abstract::Until recently, combination chemotherapy with melphalan and prednisone (MP) has remained the most widely accepted treatment option for elderly patients with multiple myeloma (MM). However, since the availability of new and more active drugs, several groups have compared in several phase III trials the efficacy and saf...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2010.530361

    authors: De La Rubia J,Sanz MA

    更新日期:2011-01-01 00:00:00

  • High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only.

    abstract::Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is a rare variant of Hodgkin's lymphoma (HL) in children. Since specific immunohistochemical staining has become available, NLPHL can be separated from classical Hodgkin's lymphoma (cHL) more accurately. Scarce information is available about pediatric NLPHL tre...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190600573291

    authors: van Grotel M,Lam KH,de Man R,Beishuizen A,Pieters R,van den Heuvel-Eibrink MM

    更新日期:2006-08-01 00:00:00

  • The clinical significance of caspase regulation in acute leukemia.

    abstract::Disruptions of pathways of programmed cell death, or apoptosis, are increasingly found in malignant cells of both solid and hematologic neoplasms. Caspases belong to a family of cysteine proteases and have emerged as central regulators of the apoptotic cascade. Despite many and diverse signals that can trigger apoptos...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190109097646

    authors: Faderl S,Estrov Z

    更新日期:2001-02-01 00:00:00

  • Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma.

    abstract::High-dose melphalan (HDM) followed by autologous hematopoietic cell transplantation (auto-HCT) remains the standard-of-care therapy for multiple myeloma (MM) even with the availability of proteasome inhibitors and immunomodulatory drugs. Gastrointestinal (GI) toxicity is the main cause of morbidity after HDM. Amifosti...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2017.1408086

    authors: Malek E,Gupta V,Creger R,Caimi P,Vatsayan A,Covut F,Bashir Q,Champlin R,Delgado R,Rondon G,Cooper B,de Lima M,Lazarus HM,Qazilbash M

    更新日期:2018-08-01 00:00:00

  • Comparison of pentostatin and alpha interferon in splenectomized patients with active hairy cell leukemia: an intergroup study. Cancer and Leukemia Group B and South-West Oncology Group.

    abstract::In 90 splenectomized patients with active HCL, this multi-institutional intergroup study showed that as compared to alpha interferon (aIF), pentostatin resulted in a higher incidence of response, but the difference was not statistically significantly. Pentostatin-induced remissions occurred significantly faster and su...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Rai KR

    更新日期:1994-01-01 00:00:00

  • Augmentation of the activity of an immunotoxin, anti-Tac(Fv)-PE40KDEL, in T cell lines infected with human T cell leukemia virus type-I.

    abstract::Therapy with an immunotoxin, anti-Tac(Fv)-PE38, which is a conjugate of the variable domains of an anti-Tac monoclonal antibody and Pseudomonas exotoxin, was reported to be useful for adult T cell leukemia (ATL) patients but a considerable amount of the immunotoxin is needed for the therapy and some side effects were ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190290017042

    authors: Ohno N,Kreitman RJ,Saito T,Masamoto I,Uozumi K,Hanada S,Takeuchi S,Furukawa T,Sumizawa T,Arima T,Akiyama S

    更新日期:2002-04-01 00:00:00

  • An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia.

    abstract::This open-label, phase 1 study evaluated the effects of ofatumumab on QTc intervals, safety, efficacy, B-cell and neutrophil counts, complement levels, and cytokine and chemokine concentrations. Fourteen patients with fludarabine-refractory chronic lymphocytic leukemia received 12 ofatumumab infusions. A higher maximu...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.3109/10428194.2015.1014357

    authors: Patton WN,Lindeman R,Butler AC,Kipps TJ,Jewell RC,Laubscher KH,Zhou YY,Lewis E,Sedoti D,Witman P,Fang L,Chan G

    更新日期:2015-01-01 00:00:00

  • Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation.

    abstract::We aimed to identify whether the use of autologous hematopoietic cell transplantation (HCT) impacts outcomes for multiple myeloma patients with gains of chromosome 1q (+1q). We retrospectively identified 95 patients, 21% having +1q. For patients with +1q, the overall response rate to induction was 85%, with 40% having...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1260126

    authors: Shah GL,Landau H,Londono D,Devlin SM,Kosuri S,Lesokhin AM,Lendvai N,Hassoun H,Chung DJ,Koehne G,Jhanwar SC,Landgren O,Levine R,Giralt SA

    更新日期:2017-08-01 00:00:00

  • Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline induction.

    abstract::After a first course of induction chemotherapy, 30-40% of patients with acute myeloid leukemia (AML) do not achieve a complete response (CR). A second course of an anthracycline and intermediate-dose cytarabine (IDAC) allows a significant number of patients with persistent AML at day 14 to finally achieve a CR. We hyp...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.685733

    authors: Prébet T,Jean E,Autret A,Charbonnier A,Rey J,Etienne A,D'incan E,Fürst S,Arnoulet C,Blaise D,Vey N

    更新日期:2012-11-01 00:00:00

  • The impact of time from diagnosis to treatment in diffuse large B-cell lymphoma.

    abstract::Diffuse large B-cell lymphoma (DLBCL) is a high-grade lymphoma that requires treatment. We retrospectively analyzed the impact of time from diagnosis-to-treatment (TDT) on progression-free survival (PFS) and overall survival (OS) in 581 R-CHOP-treated patients. TDT was defined as the interval between diagnostic biopsy...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2017.1422863

    authors: Phipps C,Lee YS,Ying H,Nagarajan C,Grigoropoulos N,Chen Y,Tang T,Goh AZ,Ghosh A,Ng HJ,Gopalakrishnan S,Loh Y,Lim ST,Hwang W,Tan D,Goh YT

    更新日期:2018-10-01 00:00:00

  • Influence of low dose rIL-2 treatment on endogenous cytokine production, expression of surface IL-2R and the level of soluble IL-2R in patients with minimal residual disease.

    abstract::This study was designed to investigate the immunomodulatory effect of low-dose IL-2 therapy (100 microg/day for 3 weeks) on interferon (IFN), tumor necrosis factor (TNF) production in vivo and in vitro and on the expression of IL-2Ralpha/beta and soluble form of IL-2Ralpha. Patients enrolled in the study suffered from...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199909145740

    authors: Dmoszyńska A,Kandefer-Szerszeń M,Roliński J,Legieć W,Kamińska T

    更新日期:1999-10-01 00:00:00

  • Diversity in antibody-based approaches to non-Hodgkin lymphoma.

    abstract::Non-Hodgkin lymphoma (NHL) remains one of the most common cancers in the US, with survival dependent on the type and stage of disease. B-cell lymphomas account for approximately 85% of all cases of NHL, and are commonly treated with chemotherapy, or monoclonal antibodies (mAbs) that target CD20 antigens on the surface...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2010.500047

    authors: Maloney D,Morschhauser F,Linden O,Hagenbeek A,Gisselbrecht C

    更新日期:2010-08-01 00:00:00

  • Bryostatin induces protein kinase C modulation, Mcl-1 up-regulation and phosphorylation of Bcl-2 resulting in cellular differentiation and resistance to drug-induced apoptosis in B-cell chronic lymphocytic leukemia cells.

    abstract::Bryostatin, a macrocyclic lactone and protein kinase C (PKC) modulator, has been shown to have differentiation and anti-tumor activity against several leukemia cell lines in vitro. In this study, we demonstrated Bryostatin-induced differentiation in B-cell chronic lymphocytic leukemia (B-CLL) cells, characterized by a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190310001639470

    authors: Thomas A,Pepper C,Hoy T,Bentley P

    更新日期:2004-05-01 00:00:00

  • Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte colony-stimulating factor (FLAG-GCSF).

    abstract::The aim of the present study was to evaluate the efficacy of the combination of fludarabine 30/mg/m2 + cytarabine 2g/m2 followed by the administration of G-CSF to achieve a complete remission (CR) in patients with relapsed acute lymphoblastic leukemia (ALL). We treated twelve patients in first relapse, overall 10 pati...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428199709039047

    authors: Montillo M,Tedeschi A,Centurioni R,Leoni P

    更新日期:1997-05-01 00:00:00

  • Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future.

    abstract::Abstract Acute graft-versus-host disease (GVHD) has compromised and continues to compromise the benefits associated with allogeneic hematopoietic cell transplant to cure malignant and non-malignant diseases. Pharmacologic interventions to prevent GVHD have emerged as a major objective of research in the immunology and...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2012.762978

    authors: Ram R,Storb R

    更新日期:2013-08-01 00:00:00